Primary antibodies used in this work were β-actin (Abcam, ab8226), SNAI1 EC3 (ref20 (link).), PY99 (Santa Cruz, sc7020), PDGFR-β (Cell Signaling, 3169), ERK1/2 (Cell Signaling, 9102), p-ERK1/2 (Cell Signaling, 9109), Akt (Cell Signaling, 4691), p-Akt (Cell Signaling, 4060), FAK (Cell Signaling, 3285), p-FAK (Cell Signaling, 3281), VE-Cadherin (Abcam, ab33168), VCAM-1 (Abcam, ab98954), MMP-9 (Abcam, ab38898), Snail (ref20 (link).), MT1-MMP (Abcam, ab51074), CD31/PCAM-1 (1:10, SC-506) Fibronectin (DAKO, A0245), Beta 1 integrin (Cell Signaling, 34971 S), Beta 3 integrin (Cell signaling, 13166 S), NF-KB p65 (Cell signaling, 8242 S), Phospho-NF-KBp65 (Cell signaling 3033 S) and Collagen I (Abcam, ab34710). Secondary antibodies used were anti-Mouse or anti-Rabbit IgG Antibody DyLight™ 680 or 800 Conjugate.
Other compounds used were PDGF-BB (Peprotech, 100-14B), BAPN: 3-Aminopropionitrile fumarate salt (Sigma, A3134), FAK inhibitor, PF-573228 (PZ0117, Sigma), ERK inhibitor, U0126-monoethanolate (Sigma, U120) and PI3K/Akt inhibitor LY294002 hydrochloride (Sigma, L9908).
Other compounds used were PDGF-BB (Peprotech, 100-14B), BAPN: 3-Aminopropionitrile fumarate salt (Sigma, A3134), FAK inhibitor, PF-573228 (PZ0117, Sigma), ERK inhibitor, U0126-monoethanolate (Sigma, U120) and PI3K/Akt inhibitor LY294002 hydrochloride (Sigma, L9908).
Free full text: Click here
